S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:CHRS

Coherus BioSciences Competitors

$15.83
+0.59 (+3.87 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.77
Now: $15.83
$15.86
50-Day Range
$15.25
MA: $17.76
$21.39
52-Week Range
$10.86
Now: $15.83
$22.22
Volume2.14 million shs
Average Volume1.56 million shs
Market Capitalization$1.15 billion
P/E Ratio7.76
Dividend YieldN/A
Beta1.57

Competitors

Coherus BioSciences (NASDAQ:CHRS) Vs. BEAM, SWTX, RLAY, RVMD, NK, and EDIT

Should you be buying CHRS stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Coherus BioSciences, including Beam Therapeutics (BEAM), SpringWorks Therapeutics (SWTX), Relay Therapeutics (RLAY), Revolution Medicines (RVMD), NantKwest (NK), and Editas Medicine (EDIT).

Coherus BioSciences (NASDAQ:CHRS) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Coherus BioSciences and Beam Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$356.07 million3.24$89.83 million$1.2312.87
Beam Therapeutics$20,000.00210,416.58$-78,330,000.00($14.05)-5.17

Coherus BioSciences has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Coherus BioSciences and Beam Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01402.80
Beam Therapeutics03302.50

Coherus BioSciences presently has a consensus price target of $26.50, indicating a potential upside of 67.40%. Beam Therapeutics has a consensus price target of $96.00, indicating a potential upside of 32.23%. Given Coherus BioSciences' stronger consensus rating and higher possible upside, research analysts clearly believe Coherus BioSciences is more favorable than Beam Therapeutics.

Institutional and Insider Ownership

49.8% of Beam Therapeutics shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Coherus BioSciences and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences33.06%90.98%27.33%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Summary

Coherus BioSciences beats Beam Therapeutics on 11 of the 13 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Coherus BioSciences (NASDAQ:CHRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Earnings & Valuation

This table compares SpringWorks Therapeutics and Coherus BioSciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.96
Coherus BioSciences$356.07 million3.24$89.83 million$1.2312.87

Coherus BioSciences has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for SpringWorks Therapeutics and Coherus BioSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00303.00
Coherus BioSciences01402.80

SpringWorks Therapeutics presently has a consensus target price of $91.00, indicating a potential upside of 22.31%. Coherus BioSciences has a consensus target price of $26.50, indicating a potential upside of 67.40%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than SpringWorks Therapeutics.

Profitability

This table compares SpringWorks Therapeutics and Coherus BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Coherus BioSciences33.06%90.98%27.33%

Institutional and Insider Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Comparatively, 15.9% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Coherus BioSciences beats SpringWorks Therapeutics on 10 of the 13 factors compared between the two stocks.

Relay Therapeutics (NASDAQ:RLAY) and Coherus BioSciences (NASDAQ:CHRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Relay Therapeutics and Coherus BioSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relay Therapeutics01502.83
Coherus BioSciences01402.80

Relay Therapeutics currently has a consensus price target of $57.40, indicating a potential upside of 53.52%. Coherus BioSciences has a consensus price target of $26.50, indicating a potential upside of 67.40%. Given Coherus BioSciences' higher probable upside, analysts plainly believe Coherus BioSciences is more favorable than Relay Therapeutics.

Earnings & Valuation

This table compares Relay Therapeutics and Coherus BioSciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay TherapeuticsN/AN/AN/AN/AN/A
Coherus BioSciences$356.07 million3.24$89.83 million$1.2312.87

Coherus BioSciences has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares Relay Therapeutics and Coherus BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relay TherapeuticsN/AN/AN/A
Coherus BioSciences33.06%90.98%27.33%

Insider and Institutional Ownership

98.4% of Relay Therapeutics shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Coherus BioSciences beats Relay Therapeutics on 6 of the 9 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Coherus BioSciences (NASDAQ:CHRS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Analyst Ratings

This is a breakdown of current ratings and target prices for Revolution Medicines and Coherus BioSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
Coherus BioSciences01402.80

Revolution Medicines currently has a consensus price target of $50.75, suggesting a potential upside of 11.54%. Coherus BioSciences has a consensus price target of $26.50, suggesting a potential upside of 67.40%. Given Coherus BioSciences' higher possible upside, analysts clearly believe Coherus BioSciences is more favorable than Revolution Medicines.

Profitability

This table compares Revolution Medicines and Coherus BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Coherus BioSciences33.06%90.98%27.33%

Earnings & Valuation

This table compares Revolution Medicines and Coherus BioSciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million60.36$-47,660,000.00N/AN/A
Coherus BioSciences$356.07 million3.24$89.83 million$1.2312.87

Coherus BioSciences has higher revenue and earnings than Revolution Medicines.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are held by institutional investors. 15.9% of Coherus BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Coherus BioSciences beats Revolution Medicines on 7 of the 9 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Coherus BioSciences and NantKwest, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01402.80
NantKwest00103.00

Coherus BioSciences currently has a consensus target price of $26.50, suggesting a potential upside of 67.40%. NantKwest has a consensus target price of $18.00, suggesting a potential downside of 32.84%. Given Coherus BioSciences' higher possible upside, equities research analysts clearly believe Coherus BioSciences is more favorable than NantKwest.

Profitability

This table compares Coherus BioSciences and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences33.06%90.98%27.33%
NantKwest-76,658.58%-56.06%-46.93%

Volatility and Risk

Coherus BioSciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500.

Valuation and Earnings

This table compares Coherus BioSciences and NantKwest's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$356.07 million3.24$89.83 million$1.2312.87
NantKwest$40,000.0073,027.99$-65,790,000.00($0.70)-38.29

Coherus BioSciences has higher revenue and earnings than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. 15.9% of Coherus BioSciences shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Coherus BioSciences beats NantKwest on 9 of the 14 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Institutional & Insider Ownership

87.5% of Editas Medicine shares are held by institutional investors. 15.9% of Coherus BioSciences shares are held by company insiders. Comparatively, 0.9% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Coherus BioSciences and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences33.06%90.98%27.33%
Editas Medicine-99.62%-26.74%-16.38%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Coherus BioSciences and Editas Medicine, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01402.80
Editas Medicine34302.00

Coherus BioSciences currently has a consensus target price of $26.50, suggesting a potential upside of 67.40%. Editas Medicine has a consensus target price of $49.2222, suggesting a potential upside of 18.24%. Given Coherus BioSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Coherus BioSciences is more favorable than Editas Medicine.

Volatility and Risk

Coherus BioSciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Valuation and Earnings

This table compares Coherus BioSciences and Editas Medicine's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$356.07 million3.24$89.83 million$1.2312.87
Editas Medicine$20.53 million136.60$-133,750,000.00($2.68)-15.53

Coherus BioSciences has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

Coherus BioSciences beats Editas Medicine on 11 of the 14 factors compared between the two stocks.


Coherus BioSciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.60+1.2%$4.21 billion$20,000.00-5.17Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.6$74.40+6.9%$3.64 billionN/A-42.76Analyst Report
High Trading Volume
Gap Up
RLAY
Relay Therapeutics
1.8$37.39+7.0%$3.36 billionN/A0.00Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$45.50+6.7%$3.02 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
NantKwest logo
NK
NantKwest
1.1$26.80+3.9%$2.92 billion$40,000.00-37.75Decrease in Short Interest
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.4$41.63+3.1%$2.80 billion$20.53 million-23.93Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$63.37+3.7%$2.79 billion$125.57 million-37.06Earnings Announcement
Analyst Report
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.88+0.8%$2.49 billion$31.43 million-6.08Analyst Revision
News Coverage
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.18+4.8%$2.14 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
AlloVir logo
ALVR
AlloVir
1.4$30.52+13.1%$1.99 billionN/A0.00Insider Selling
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15+2.1%$1.98 billion$48.83 million-14.67
Vericel logo
VCEL
Vericel
1.5$42.51+4.9%$1.95 billion$117.85 million-4,251,000.00Analyst Report
Analyst Revision
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.68+2.6%$1.93 billion$44.67 million-2.61Analyst Report
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.53+5.5%$1.80 billion$20.49 million-22.21Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63+6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23+4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74+2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31+8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36+1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$72.74+1.5%$1.61 billionN/A-49.15Earnings Announcement
Analyst Upgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93+1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87+1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$17.07+4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.07+1.1%$1.34 billionN/A-3.48Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.51+3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76+0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Cortexyme logo
CRTX
Cortexyme
1.3$37.99+4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36+20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12+1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17+0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56+17.2%$1.02 billionN/A-5.87High Trading Volume
News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39+0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83+2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10+5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75+2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41+3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80+3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11+3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13+2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19+6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02+1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76+1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$31.54+2.9%$640.89 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.18+0.6%$623.06 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.20+1.3%$608.48 million$150.05 million-2.94
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.50+4.2%$603.52 million$22.24 million-5.72Upcoming Earnings
Analyst Report
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.21+3.6%$572.36 million$14.75 million-2.24Upcoming Earnings
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$12.60+9.1%$571.96 million$147.87 million-4.19Analyst Upgrade
News Coverage
Gap Up
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$9.40+6.1%$568.22 millionN/A-4.56Upcoming Earnings
News Coverage
Gap Up
Compugen logo
CGEN
Compugen
1.4$8.30+1.6%$567.54 million$17.80 million-22.42Analyst Downgrade
High Trading Volume
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.